|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
623,250,000 |
Market
Cap: |
17.75(B) |
Last
Volume: |
1,481,256 |
Avg
Vol: |
1,468,856 |
52
Week Range: |
$27.63 - $30.325 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 400 MIDCAP |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1197 |
Guru Rank Value : -0.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Edwards Lifesciences is focused on technologies that treat structural heart disease and ill patients. The products and technologies provided by Co. are categorized into the several main areas, including: Transcatheter Aortic Valve Replacement, which is engaged in transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves; Transcatheter Mitral and Tricuspid Therapies, which is focused on the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases; and Surgical Structural Heart, which is engaged in resilient surgical therapies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
580 |
580 |
Total Buy Value |
$0 |
$0 |
$49,753 |
$49,753 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
72,342 |
120,925 |
224,934 |
1,137,553 |
Total Sell Value |
$5,217,440 |
$8,529,242 |
$17,219,583 |
$92,782,541 |
Total People Sold |
6 |
9 |
11 |
14 |
Total Sell Transactions |
13 |
19 |
35 |
102 |
End Date |
2025-01-16 |
2024-10-15 |
2024-04-16 |
2023-04-17 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bobo Donald E Jr |
CVP,Strategy/Corp Development |
|
2025-04-14 |
4 |
AS |
$69.81 |
$663,196 |
D/D |
(9,500) |
47,206 |
|
- |
|
Bobo Donald E Jr |
CVP,Strategy/Corp Development |
|
2025-04-14 |
4 |
OE |
$45.28 |
$430,129 |
D/D |
9,500 |
56,706 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-04-08 |
4 |
AS |
$70.61 |
$21,183 |
D/D |
(300) |
22,863 |
|
2% |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-04-08 |
4 |
OE |
$45.28 |
$13,583 |
D/D |
300 |
23,163 |
|
- |
|
Bobo Donald E Jr |
CVP,Strategy/Corp Development |
|
2025-03-13 |
4 |
AS |
$67.96 |
$645,624 |
D/D |
(9,500) |
46,936 |
|
-2% |
|
Bobo Donald E Jr |
CVP,Strategy/Corp Development |
|
2025-03-13 |
4 |
OE |
$45.28 |
$430,129 |
D/D |
9,500 |
56,436 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-03-10 |
4 |
AS |
$69.48 |
$27,792 |
D/D |
(400) |
22,588 |
|
-1% |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-03-10 |
4 |
OE |
$45.28 |
$18,111 |
D/D |
400 |
22,988 |
|
- |
|
Zovighian Bernard J |
CEO |
|
2025-03-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,299 |
10,436 |
|
- |
|
Zovighian Bernard J |
CEO |
|
2025-03-10 |
4 |
AS |
$69.51 |
$428,448 |
D/D |
(6,164) |
59,083 |
|
-1% |
|
Zovighian Bernard J |
CEO |
|
2025-03-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,299 |
65,247 |
|
- |
|
Zovighian Bernard J |
CEO |
|
2025-03-10 |
4 |
OE |
$45.28 |
$337,900 |
D/D |
7,463 |
66,546 |
|
- |
|
Ullem Scott B. |
CVP, Chief Financial Officer |
|
2025-02-28 |
4 |
AS |
$70.52 |
$796,327 |
D/D |
(11,250) |
30,387 |
|
-1% |
|
Ullem Scott B. |
CVP, Chief Financial Officer |
|
2025-02-28 |
4 |
OE |
$45.28 |
$509,363 |
D/D |
11,250 |
41,637 |
|
- |
|
Dahl Andrew M. |
SVP, Corporate Controller |
|
2025-02-22 |
4 |
D |
$73.30 |
$12,901 |
D/D |
(176) |
4,684 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-02-18 |
4 |
D |
$76.19 |
$16,914 |
D/D |
(222) |
22,588 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-02-17 |
4 |
D |
$76.19 |
$12,571 |
D/D |
(165) |
22,810 |
|
- |
|
Ullem Scott B. |
CVP, Chief Financial Officer |
|
2025-02-16 |
4 |
D |
$76.19 |
$13,257 |
D/D |
(174) |
30,387 |
|
- |
|
Wood Larry L |
Global President TAVR & Surg |
|
2025-02-16 |
4 |
D |
$76.19 |
$25,371 |
D/D |
(333) |
198,193 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-02-16 |
4 |
D |
$76.19 |
$16,305 |
D/D |
(214) |
22,975 |
|
- |
|
Loranger Steven R |
Director |
|
2025-02-14 |
4 |
S |
$76.42 |
$438,576 |
D/D |
(5,739) |
60,372 |
|
2% |
|
Loranger Steven R |
Director |
|
2025-02-14 |
4 |
OE |
$45.32 |
$260,073 |
D/D |
5,739 |
66,111 |
|
- |
|
Stone Leslie Heisz |
Director |
|
2025-02-13 |
4 |
S |
$75.86 |
$435,371 |
D/D |
(5,739) |
30,035 |
|
3% |
|
Stone Leslie Heisz |
Director |
|
2025-02-13 |
4 |
OE |
$45.32 |
$260,073 |
D/D |
5,739 |
35,774 |
|
- |
|
Lippis Daniel J. |
CVP, JAPAC |
|
2025-02-13 |
4 |
AS |
$76.34 |
$38,170 |
D/D |
(500) |
23,189 |
|
-3% |
|
1781 Records found
|
|
Page 1 of 72 |
|
|